News
Instil's licensed PD-L1xVEGF bispecific shows promise in China, instilling hope for upcoming US test
A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...
AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...
After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...
Last week, Australian life sciences venture capital firm Brandon Capital closed its largest fund yet, raising A$439 million ...
AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. | AbbVie has reportedly added Gilgamesh ...
NXP800, a GCN2 kinase activator, has been on shaky ground since a data drop in November revealed a lack of efficacy. Seeking to improve outcomes, Nuvectis turned its attention to a new cohort of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback